Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Angiodynamics (ANGO) Research & Development (2016 - 2026)

Angiodynamics' Research & Development history spans 17 years, with the latest figure at $7.1 million for Q1 2026.

  • For Q1 2026, Research & Development rose 2.47% year-over-year to $7.1 million; the TTM value through Feb 2026 reached $27.9 million, up 5.7%, while the annual FY2025 figure was $26.2 million, 16.79% down from the prior year.
  • Research & Development reached $7.1 million in Q1 2026 per ANGO's latest filing, down from $7.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $8.7 million in Q4 2023 to a low of $6.3 million in Q3 2024.
  • Average Research & Development over 5 years is $7.3 million, with a median of $7.1 million recorded in 2026.
  • Peak YoY movement for Research & Development: rose 26.62% in 2023, then fell 25.69% in 2024.
  • A 5-year view of Research & Development shows it stood at $6.8 million in 2022, then rose by 26.62% to $8.7 million in 2023, then dropped by 25.69% to $6.4 million in 2024, then rose by 20.73% to $7.8 million in 2025, then dropped by 8.81% to $7.1 million in 2026.
  • Per Business Quant, the three most recent readings for ANGO's Research & Development are $7.1 million (Q1 2026), $7.8 million (Q4 2025), and $6.4 million (Q3 2025).